Diagnosis, prevention, and intervention for the metabolic syndrome
Section snippets
Prevalence
Without a unifying definition, reports of prevalence have varied in the United States and Europe.7, 8 Using the WHO definition and data from the National Health and Nutrition Examination Survey III (NHANES III) and the ATP III criteria, the age-adjusted prevalence of the metabolic syndrome in the US population is now estimated at 23.7% and increases to 43.5% in adults who are ≥60 years of age. African American and Mexican American women have significantly higher prevalence rates than do their
Features of the metabolic syndrome
The presence of abdominal obesity in subjects with IR is a powerful risk factor for the development of type 2 diabetes mellitus and cardiovascular disease.11, 12, 13, 14 Excessive visceral adipose tissue accumulation (in the presence or absence of obesity) is associated with IR, hyperinsulinemia, and glucose intolerance.15, 16, 17, 18 In addition, excess abdominal obesity is associated with a potentially atherogenic lipoprotein profile, which includes (1) hypertriglyceridemia; (2) elevated
Treating the metabolic syndrome
When a patient with metabolic syndrome is identified, the health care provider must effectively communicate the significant risk of developing overt type 2 diabetes mellitus, CAD, and stroke. The patient needs to understand that type 2 diabetes mellitus is a CAD risk equivalent.
The primary goals of treating metabolic syndrome are prevention of type 2 diabetes mellitus and cardiovascular events. According to the American Diabetes Association and the ATP III, the starting point for treatment is
Conclusion
Challenges clinicians encounter with the metabolic syndrome are early detection of IR and implementation of treatment strategies that encompass all components of the metabolic syndrome. A shift in focus in the diagnosis and treatment of the metabolic syndrome from glucose control to primary prevention, early detection, and treatment of the underlying atherogenic risk factors is needed to prevent the progression of type 2 diabetes mellitus and cardiovascular disease.
References (71)
- et al.
Role of glucose and insulin resistance in development of type 2 diabetes mellitusresults from a 25-year follow-up study
Lancet
(1992) - et al.
Dysglycemia and the risk of cardiovascular disease
Lancet
(1996) Triglycerides and atherogenic lipoproteinsrationale for lipid management
Am J Med
(1998)- et al.
Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B
Am J Med
(1993) - et al.
TRIPOD (TRoglitazone in the Prevention of Diabetes)a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus
Control Clin Trials
(1998) - et al.
Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarctionthe Cholesterol and Recurrent Events (CARE) trial
Am J Cardiol
(1991) Addressing the insulin resistance syndromea role for the thiazolidinediones
Trends Cardiovasc Med
(2002)- et al.
Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol
Prog Cardiovasc Dis
(1998) - et al.
Clustering of heart disease risk factors in diabetic compared to nondiabetic adults
Am J Epidemiol
(1983) Role of insulin resistance in human disease
Diabetes
(1988)
Connections between obesity and dyslipidemia
Curr Opin Lipidol
Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation
Diabet Med
Cardiovascular morbidity and mortality associated with the metabolic syndrome
Diabetes Care
Prevalence of insulin resistance in metabolic disordersthe Bruneck Study
Diabetes
Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects
J Intern Med
Prevalence of the metabolic syndrome among US adultsfindings from the Third National Health and Nutrition Examination Survey
JAMA
Hyperinsulinemia as an independent risk factor for ischemic heart disease
N Engl J Med
Distribution of adipose tissue and risk of cardiovascular disease and deatha 12-year follow-up of participants in the population study of women in Gothenburg, Sweden
BMJ
Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death13-year follow-up of participants in the study of men born in 1913
BMJ
The pattern of subcutaneous fat distribution in middle-aged men and the risk of coronary heart diseasethe Paris Prospective Study
Int J Obes
The influence of body fat distribution on the incidence of diabetes mellitus13.5 years of follow-up of the participants in the study of men born in 1913
Diabetes
The dense LDL phenotypeassociation with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men
Diabetes Care
Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects
Am J Physiol
Insulin resistance and cardiovascular disease
J Clin Endocrinol Metab
Diabetes, hypertension, and cardiovascular diseasean update
Hypertension
Cardiovascular risk factors in confirmed prediabetic individualsdoes the clock for coronary heart disease start ticking before the onset of clinical diabetes?
JAMA
Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitusprospective studies of Pima Indians
N Engl J Med
Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in offspring of diabetic patients
Ann Intern Med
Homozygosity for a new mutation (Ile119 → Met) in the insulin receptor gene in 5 sibs with familial insulin resistance
J Med Genet
Mutations in the insulin receptor gene
Endocr Rev
Insulin-receptor gene and its expression in patients with insulin resistance
Diabetes
Linkage of chromosomal markers on 4q with a putative gene determining maximal insulin action in Pima Indians
Diabetes
An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance
J Clin Invest
Quantitative trait loci for cellular defects in glucose and fatty acid metabolism in hypertensive rats
Nat Genet
Cited by (164)
Effect of caffeine-chitosan nanoparticles and α-lipoic acid on the cardiovascular changes induced in rat model of obesity
2024, International ImmunopharmacologyImpact of lifetime air pollution exposure patterns on the risk of chronic disease
2023, Environmental ResearchHealth benefits of functional plant polysaccharides in metabolic syndrome: An overview
2022, Journal of Functional FoodsEffects of pistachios on glycaemic control: A systematic review and meta-analysis of randomised controlled trials
2023, British Journal of NutritionA systematic review and meta-Analysis of exercise interventions in schizophrenia patients
2015, Psychological MedicineDietary management of the metabolic syndrome - One size fits all?
2013, Proceedings of the Nutrition Society